Список проголосовавших за комментарий " Cara Therapeutics target raised to $20 at Laidlaw; Buy (17.49)Laidlaw raises their CARA tgt to $20 from $17 after reporting Q4 last night after the close and the old bard Mark Twain's words were never truer than with CARA and the anticipation for data in March (IV for pruritus data) and 2Q17. CARA has one of the most interesting 1H17s coming up of any name in their coverage space, with multiple data read outs that target huge markets (pain) and huge & currently unserved by approved drugs (pruritus). Outside of R&D coming in significantly higher than firm's expectations no real news on the quarter; the story remains the upcoming data read outs and the subsequent FDA meetings to determine the appropriate path forward. Given the early data in pain & pruritus CARA has already demonstrated over the past, <strong>firm continues to believe the ongoing trials have a high probability of also posting positive data positioning CARA for significant advancement through 2017.</strong>"